AYAHUASCA: Uses, Side Effects, Interactions and Warnings

AYAHUASCA

Other Names:

Appane, Ayahoasca, Caapi, Chacrona, Chacruna, Chaliponga, Daime, Dapa, Hoasca, Jagube, Jurema, Kawa, Mariri, Mihi, Natem, Ooasca, Orhoasca, Queen, Rainha, Soulvine, Yagé, Yajé.

Review this Treatment 5 User Reviews See Brand Products

AYAHUASCA Overview Information

Ayahuasca is an herbal drink used during certain rituals in countries in the Amazon. It contains chemicals that affect the brain and might be unsafe.

The word "ayahuasca" comes from the words, aya, meaning spirit or soul, and huasca, meaning rope or vine, in the Quechua language. Ayahuasca is often made from the plants Banisteriopsis caapi and Psychotria viridis. The chemicals in ayahuasca are of interest for reducing symptoms of depression and improving mood.

Ayahuasca is used for suicide prevention, depression, grief, and many other conditions, but there is no good scientific evidence to support these uses.

AYAHUASCA Uses & Effectiveness

We currently have no information for AYAHUASCA Uses & Effectiveness

AYAHUASCA Side Effects & Safety

When taken by mouth: Ayahuasca is possibly unsafe. Ayahuasca contains chemicals that can cause hallucinations, tremors, dilated pupils, increased blood pressure, nausea, and vomiting. Life-threatening side effects and death have also been linked with ayahuasca use.

Special Precautions & Warnings:

Pregnancy and breast-feeding: Ayahuasca is likely unsafe when taken while pregnant and breast-feeding. Along with causing hallucinations and other serious side effects, ayahuasca might be toxic to the fetus if used during pregnancy. Avoid using.

Anxiety: Ayahuasca might increase the risk of various mental health effects in people with anxiety. Don't use ayahuasca if you have anxiety.

Bipolar disorder: Ayahuasca might increase the risk of having a manic episode in people with bipolar disorder. Don't use ayahuasca if you have bipolar disorder.

Hallucinations and delusions (psychosis): Ayahuasca might increase the severity of hallucinations in people with psychosis. Don't use ayahuasca if you have psychosis.

AYAHUASCA Interactions

Moderate Interaction Be cautious with this combination

Medications changed by the liver (Cytochrome P450 2D6 (CYP2D6) substrates) interacts with AYAHUASCA
Some medications are changed and broken down by the liver. Ayahuasca might change how quickly the liver breaks down these medications. This could change the effects and side effects of these medications.
Medications changed by the liver (Cytochrome P450 3A4 (CYP3A4) substrates) interacts with AYAHUASCA
Some medications are changed and broken down by the liver. Ayahuasca might change how quickly the liver breaks down these medications. This could change the effects and side effects of these medications.
Medications used for Parkinson disease (Dopamine agonists) interacts with AYAHUASCA
Ayahuasca contains chemicals that can affect the brain. Taking ayahuasca with medications used for Parkinson disease might increase the effects and side effects of these medications
Serotonergic Drugs interacts with AYAHUASCA
Ayahuasca might increase a brain chemical called serotonin. Some medications also have this effect. Taking ayahuasca along with these medications might increase serotonin too much. This might cause serious side effects including heart problems, seizures, and vomiting.

AYAHUASCA Dosing

Ayahuasca is an herbal drink. The contents of the drink vary depending on the plants used and how they are prepared. Ayahuasca contains the chemical dimethyltryptamine (DMT) which might be unsafe. There isn't enough reliable information to know what an appropriate dose of ayahuasca might be.

View clinical references for this vitamin or supplement Sources

References:

Abdel-Fattah, A. F., Matsumoto, K., Murakami, Y., Adel-Khalek, Gammaz H., Mohamed, M. F., and Watanabe, H. Central serotonin level-dependent changes in body temperature following administration of tryptophan to pargyline- and harmaline-pretreated rats. Gen Pharmacol 1997;28(3):405-409. View abstract.

Alves CL, Cury RG, Roster K, et al. Application of machine learning and complex network measures to an EEG dataset from ayahuasca experiments. PLoS One 2022;17(12):e0277257. View abstract.

Barbosa PC, Mizumoto S, Bogenschutz MP, Strassman RJ. Health status of ayahuasca users. Drug Test Anal. 2012 Jul-Aug;4(7-8):601-9. View abstract.

Bayat Mokhtari M, Bayat Mokhtari M, Rodriguez BZ, Yen TY, Rodriguez ID. Syndrome of inappropriate antidiuretic hormone secretion following ayahuasca use in a satanic ritual: A case report. Cureus 2022;14(4):e24310. View abstract.

Bergstrom, M., Westerberg, G., and Langstrom, B. 11C-harmine as a tracer for monoamine oxidase A (MAO-A): in vitro and in vivo studies. Nucl Med Biol 1997;24(4):287-293. View abstract.

Bouso JC, Andión Ó, Sarris JJ, et al. Adverse effects of ayahuasca: Results from the Global Ayahuasca Survey. PLOS Glob Public Health 2022;2(11):e0000438. View abstract.

Breeksema JJ, Kuin BW, Kamphuis J, van den Brink W, Vermetten E, Schoevers RA. Adverse events in clinical treatments with serotonergic psychedelics and MDMA: A mixed-methods systematic review. J Psychopharmacol 2022;36(10):1100-1117. View abstract.

Callaway JC, Grob CS. Ayahuasca preparations and serotonin reuptake inhibitors: a potential combination for severe adverse interactions. J Psychoactive Drugs. 1998 Oct-Dec;30(4):367-9. View abstract.

Callaway JC. Fast and slow metabolizers of Hoasca. J Psychoactive Drugs. 2005 Jun;37(2):157-61. View abstract.

Cerón Tapia HR, González Guzmán MA, Córdoba Ortiz SA. Ayahuasca-induced psychosis: A case report. Rev Colomb Psiquiatr (Engl Ed) 2022;51(3):236-239. View abstract.

Daldegan-Bueno D, Favaro VM, Morais PR, Sussulini A, Oliveira MGM. Effects of repeated ayahuasca administration on behaviour and c-Fos expression in male rats exposed to the open field. Behav Brain Res 2022;427:113878. View abstract.

de Sousa GM, de Oliveira Tavares VD, de Menezes Galvão AC, et al. Moderators of ayahuasca's biological antidepressant action. Front Psychiatry 2022;13:1033816. View abstract.

Dos Santos RG, Balthazar FM, Bouso JC, Hallak JE. The current state of research on ayahuasca: A systematic review of human studies assessing psychiatric symptoms, neuropsychological functioning, and neuroimaging. J Psychopharmacol. 2016 Jun 10. pii: 0269881116652578. View abstract.

Dos Santos RG, Grasa E, Valle M, et al. Pharmacology of ayahuasca administered in two repeated doses. Psychopharmacology (Berl). 2012 Feb;219(4):1039-53. View abstract.

Dos Santos RG, Osório FL, Crippa JA, Riba J, Zuardi AW, Hallak JE. Antidepressive, anxiolytic, and antiaddictive effects of ayahuasca, psilocybin and lysergic acid diethylamide (LSD): a systematic review of clinical trials published in the last 25 years. Ther Adv Psychopharmacol. 2016 Jun;6(3):193-213. View abstract.

Dos Santos RG, Osório FL, Rocha JM, et al. Ayahuasca Improves Self-perception of Speech Performance in Subjects With Social Anxiety Disorder: A Pilot, Proof-of-Concept, Randomized, Placebo-Controlled Trial. J Clin Psychopharmacol. 2021. View abstract.

Dos Santos RG, Rocha JM, Rossi GN, et al. Effects of ayahuasca on the endocannabinoid system of healthy volunteers and in volunteers with social anxiety disorder: Results from two pilot, proof-of-concept, randomized, placebo-controlled trials. Hum Psychopharmacol 2022;37(4):e2834. View abstract.

Dos Santos RG, Valle M, Bouso JC, et al. Autonomic, neuroendocrine, and immunological effects of ayahuasca: a comparative study with d-amphetamine. J Clin Psychopharmacol. 2011 Dec;31(6):717-26. View abstract.

dos Santos RG. A critical evaluation of reports associating ayahuasca with life-threatening adverse reactions. J Psychoactive Drugs. 2013 Apr-Jun;45(2):179-88. View abstract.

dos Santos RG. Safety and side effects of ayahuasca in humans--an overview focusing on developmental toxicology. J Psychoactive Drugs. 2013 Jan-Mar;45(1):68-78. View abstract.

Fuller, R. W., Wong, C. J., and Hemrick-Luecke, S. K. MD 240928 and harmaline: opposite selectivity in antagonism of the inactivation of types A and B monoamine oxidase by pargyline in mice. Life Sci 1986;38(5):409-412. View abstract.

Gerardy, J. Effect of moclobemide on rat brain monoamine oxidase A and B: comparison with harmaline and clorgyline. Prog Neuropsychopharmacol Biol Psychiatry 1994;18(4):793-802. View abstract.

Gianfratti B, Tabach R, Sakalem ME, Stessuk T, Maia LO, Carlini EA. Ayahuasca blocks ethanol preference in an animal model of dependence and shows no acute toxicity. J Ethnopharmacol 2022;285:114865. View abstract.

Giovannetti C, Garcia Arce S, Rush B, Mendive F. Pilot Evaluation of a Residential Drug Addiction Treatment Combining Traditional Amazonian Medicine, Ayahuasca and Psychotherapy on Depression and Anxiety. J Psychoactive Drugs. 2020;52(5):472-481. View abstract.

Gómez-Sousa M, Jiménez-Garrido DF, Ona G, et al. Acute Psychological Adverse Reactions in First-Time Ritual Ayahuasca Users: A Prospective Case Series. J Clin Psychopharmacol. 2021;41(2):163-171. View abstract.

González D, Cantillo J, Pérez I, et al. Therapeutic potential of ayahuasca in grief: a prospective, observational study. Psychopharmacology (Berl). 2020;237(4):1171-1182. View abstract.

Herraiz, T., Gonzalez, D., Ancin-Azpilicueta, C., Aran, V. J., and Guillen, H. beta-Carboline alkaloids in Peganum harmala and inhibition of human monoamine oxidase (MAO). Food Chem Toxicol 2010;48(3):839-845. View abstract.

Iurlo, M., Leone, G., Schilstrom, B., Linner, L., Nomikos, G., Hertel, P., Silvestrini, B., and Svensson, H. Effects of harmine on dopamine output and metabolism in rat striatum: role of monoamine oxidase-A inhibition. Psychopharmacology (Berl) 2001;159(1):98-104. View abstract.

Jiménez-Garrido DF, Gómez-Sousa M, Ona G, et al. Effects of ayahuasca on mental health and quality of life in naïve users: A longitudinal and cross-sectional study combination. Sci Rep. 2020;10(1):4075. View abstract.

Kaasik H, Souza RCZ, Zandonadi FS, Tófoli LF, Sussulini A. Chemical Composition of Traditional and Analog Ayahuasca. J Psychoactive Drugs. 2021;53(1):65-75. View abstract.

Kawanishi, K., Hashimoto, Y., Fujiwara, M., Kataoka, Y., and Ueki, S. Pharmacological characteristics of abnormal behavior induced by harmine with special reference to tremor in mice. J Pharmacobiodyn 1981;4(7):520-527. View abstract.

Kohek M, Ona G, van Elk M, et al. Ayahuasca and public health II: Health status in a large sample of ayahuasca-ceremony participants in the Netherlands. J Psychoactive Drugs 2022. View abstract.

Ledwos N, Rosenblat JD, Blumberger DM, et al. A critical appraisal of evidence on the efficacy and safety of serotonergic psychedelic drugs as emerging antidepressants: Mind the evidence gap. J Clin Psychopharmacol 2022;42(6):581-588. View abstract.

Lesiak AD, Musah RA. Application of ambient ionization high resolution mass spectrometry to determination of the botanical provenance of the constituents of psychoactive drug mixtures. Forensic Sci Int. 2016 Sep;266:271-80. View abstract.

McIlhenny EH, Riba J, Barbanoj MJ, Strassman R, Barker SA. Methodology for and the determination of the major constituents and metabolites of the Amazonian botanical medicine ayahuasca in human urine. Biomed Chromatogr. 2011 Sep;25(9):970-84. View abstract.

Mello SM, Soubhia PC, Silveira G, et al. Effect of ritualistic consumption of ayahuasca on hepatic function in chronic users. J Psychoactive Drugs. 2019;51(1):3-11. View abstract.

Murphy-Beiner A, Soar K. Ayahuasca's 'afterglow': improved mindfulness and cognitive flexibility in ayahuasca drinkers. Psychopharmacology (Berl). 2020;237(4):1161-1169. View abstract.

Nunes AA, Dos Santos RG, Osório FL, Sanches RF, Crippa JA, Hallak JE. Effects of Ayahuasca and its Alkaloids on Drug Dependence: A Systematic Literature Review of Quantitative Studies in Animals and Humans. J Psychoactive Drugs. 2016 Jul-Aug;48(3):195-205. View abstract.

Ona G, Kohek M, Massaguer T, et al. Ayahuasca and public health: Health status, psychosocial well-being, lifestyle, and coping strategies in a large sample of ritual ayahuasca users. J Psychoactive Drugs. 2019;51(2):135-145. View abstract.

Osório Fde L, Sanches RF, Macedo LR, et al. Antidepressant effects of a single dose of ayahuasca in patients with recurrent depression: a preliminary report. Rev Bras Psiquiatr. 2015 Jan-Mar;37(1):13-20. View abstract.

Palhano-Fontes F, Barreto D, Onias H, et al. Rapid antidepressant effects of the psychedelic ayahuasca in treatment-resistant depression: a randomized placebo-controlled trial. Psychol Med. 2019;49(4):655-663. View abstract.

Palma-Álvarez RF, Grau-López L, Ros-Cucurull E, et al. Psychosis induced by abuse of ayahuasca: a case report. Rev Colomb Psiquiatr (Engl Ed). 2021;50(1):43-46. View abstract.

Perkins D, Pagni BA, Sarris J, Barbosa PCR, Chenhall R. Changes in mental health, wellbeing and personality following ayahuasca consumption: Results of a naturalistic longitudinal study. Front Pharmacol 2022;13:884703. View abstract.

Pomilio AB, Vitale AA, Ciprian-Ollivier J, Cetkovich-Bakmas M, Gómez R, Vázquez G. Ayahoasca: an experimental psychosis that mirrors the transmethylation hypothesis of schizophrenia. J Ethnopharmacol. 1999 Apr;65(1):29-51. View abstract.

Riba J, Rodríguez-Fornells A, Urbano G, et al. Subjective effects and tolerability of the South American psychoactive beverage Ayahuasca in healthy volunteers. Psychopharmacology (Berl). 2001 Feb;154(1):85-95. View abstract.

Rocha JM, Rossi GN, de Lima Osório F, et al. Effects of Ayahuasca on the Recognition of Facial Expressions of Emotions in Naive Healthy Volunteers: A Pilot, Proof-of-Concept, Randomized Controlled Trial. J Clin Psychopharmacol. 2021;41(3):267-274. View abstract.

Rocha JM, Rossi GN, Osorio FL, Hallak JEC, Dos Santos RG. Adverse Effects After Ayahuasca Administration in the Clinical Setting. J Clin Psychopharmacol 2022;42(3):321-324. View abstract.

Rosenblat JD, Husain MI, Lee Y, et al. The Canadian Network for Mood and Anxiety Treatments (CANMAT) Task Force Report: Serotonergic Psychedelic Treatments for Major Depressive Disorder. Can J Psychiatry 2023;68(1):5-21. View abstract.

Sacher, J., Houle, S., Parkes, J., Rusjan, P., Sagrati, S., Wilson, A. A., and Meyer, J. H. Monoamine oxidase A inhibitor occupancy during treatment of major depressive episodes with moclobemide or St. John's wort: an [11C]-harmine PET study. J Psychiatry Neurosci 2011;36(6):375-382. View abstract.

Sanches RF, de Lima Osório F, Dos Santos RG, et al. Antidepressant Effects of a Single Dose of Ayahuasca in Patients With Recurrent Depression: A SPECT Study. J Clin Psychopharmacol. 2016 Feb;36(1):77-81. View abstract.

Schenberg EE. Ayahuasca and cancer treatment. SAGE Open Med. 2013 Oct 18;1:2050312113508389. View abstract.

Simonsson O, Bouso JC, Kurth F, et al. Preliminary evidence of links between ayahuasca use and the corpus callosum. Front Psychiatry 2022;13:1002455. View abstract.

Sklerov J, Levine B, Moore KA, King T, Fowler D. A fatal intoxication following the ingestion of 5-methoxy-N,N-dimethyltryptamine in an ayahuasca preparation. J Anal Toxicol. 2005 Nov-Dec;29(8):838-41. View abstract.

Szmulewicz AG, Valerio MP, Smith JM. Switch to mania after ayahuasca consumption in a man with bipolar disorder: a case report. Int J Bipolar Disord. 2015 Feb 24;3:4. View abstract.

Thomas G, Lucas P, Capler NR, Tupper KW, Martin G. Ayahuasca-assisted therapy for addiction: results from a preliminary observational study in Canada. Curr Drug Abuse Rev. 2013 Mar;6(1):30-42. View abstract.

Uthaug MV, Mason NL, Toennes SW, et al. A placebo-controlled study of the effects of ayahuasca, set and setting on mental health of participants in ayahuasca group retreats. Psychopharmacology (Berl). 2021 Jul;238(7):1899-1910. View abstract.

Uthaug MV, van Oorsouw K, Kuypers KPC, et al. Sub-acute and long-term effects of ayahuasca on affect and cognitive thinking style and their association with ego dissolution. Psychopharmacology (Berl). 2018;235(10):2979-2989. View abstract.

Yritia M, Riba J, Ortuño J, et al. Determination of N,N-dimethyltryptamine and beta-carboline alkaloids in human plasma following oral administration of Ayahuasca. J Chromatogr B Analyt Technol Biomed Life Sci. 2002 Nov 5;779(2):271-81. View abstract.

Zeifman RJ, Palhano-Fontes F, Hallak J, Arcoverde E, Maia-Oliveira JP, Araujo DB. The impact of ayahuasca on suicidality: Results from a randomized controlled trial. Front Pharmacol. 2019;10:1325. View abstract.

Zeifman RJ, Singhal N, Dos Santos RG, et al. Rapid and sustained decreases in suicidality following a single dose of ayahuasca among individuals with recurrent major depressive disorder: results from an open-label trial. Psychopharmacology (Berl). 2021;238(2):453-459. View abstract.

Zhao, T., He, Y. Q., Wang, J., Ding, K. M., Wang, C. H., and Wang, Z. T. Inhibition of human cytochrome P450 enzymes 3A4 and 2D6 by β-carboline alkaloids, harmine derivatives. Phytother Res 2011;25(11):1671-1677. View abstract.

See 5 Reviews for this Treatment - OR -

Learn about User Reviews and read IMPORTANT information about user generated content

Conditions of Use and Important Information: This information is meant to supplement, not replace advice from your doctor or healthcare provider and is not meant to cover all possible uses, precautions, interactions or adverse effects. This information may not fit your specific health circumstances. Never delay or disregard seeking professional medical advice from your doctor or other qualified health care provider because of something you have read on WebMD. You should always speak with your doctor or health care professional before you start, stop, or change any prescribed part of your health care plan or treatment and to determine what course of therapy is right for you.

This copyrighted material is provided by Natural Medicines Comprehensive Database Consumer Version. Information from this source is evidence-based and objective, and without commercial influence. For professional medical information on natural medicines, see Natural Medicines Comprehensive Database Professional Version. © Therapeutic Research Faculty 2009.

Today on WebMD